The foundation Fundación Alivia on 29 October 2026 published its October update to the OncoIndex list for Spain . According to the report, of 181 cancer therapies examined, 43 are fully publicly funded and available without restrictions, 97 are subject to access restrictions, and 41 are not funded. In the foundation’s assessment, this means that only about one in four recommended therapies is available without additional obstacles.
The OncoIndex classifies cancer treatments authorised in Spain according to whether they are funded in the public system and practically available. According to Fundación Alivia, “restricted” includes, among other things, administrative requirements or rules that delay or selectively limit access. “Not funded” refers to treatments that are authorised but are not reimbursed under the state benefits system. The current assessment covers treatments for solid tumours as well as haematological diseases.
The burden of disease adds to the importance of the situation. The Sociedad Española de Oncología Médica (SEOM) cites 2026 estimates from the Spanish cancer registry network REDECAN. These put the number of expected new cases in Spain at around 301,184. At the same time, according to the latest available surveys, more than two million people are already living with a cancer diagnosis. These figures provide the context in which the rapid and broad availability of evidence-based treatments takes on particular importance.
Fundación Alivia warns that access restrictions can mean that patients are not treated in all cases in accordance with current European guidelines. This could disadvantage survival and quality of life. The foundation therefore calls for faster, more transparent assessment and funding procedures so that medical advances reach routine care sooner. At the same time, the specific causal effects of individual access barriers on care outcomes need to be robustly investigated clinically and epidemiologically; such assessments go beyond the scope of the OncoIndex.
The OncoIndex is a monitoring tool produced by Fundación Alivia that regularly documents the funding status and real-world availability of cancer therapies in Spain’s health system. The update published on 29 October 2026 provides a snapshot. Policy decisions on assessments of clinical benefit and reimbursement can change the status of individual treatments over time, and future editions of the index are intended to reflect these changes.
Editor: Mira Cadena (Article created with AI assistance).